David Campbell, Ph.D.

David Campbell, Ph.D.

President and Chief Executive OfficeratJanux Therapeutics· In proxies 2022–2025

Pay in FY2025+50% from the year before · Janux Therapeutics stock -74.2% the same year

David Campbell, Ph.D. was paid $13.5M in FY2025 (Dec), up 50%. Janux Therapeutics stock fell 74.2% that year.

Pay$100 in the stock at the end of FY21 → $70
Pay is from the Summary Compensation Table of each Janux Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Janux TherapeuticsPublic company · 4 yr
    • President and Chief Executive Officer2022 – Present · 4 yrStock in role -11%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?